Inpefa
Payments companies reported to CMS as associated with Inpefa. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Inpefa, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Inpefa
These are the largest totals companies reported as associated with Inpefa. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Krishnaswami Vijayaraghavan | Scottsdale, AZ | Cardiovascular Disease | $75,428.27 |
| Joggy George | Houston, TX | Cardiovascular Disease | $58,677.07 |
| Henry Ward | New Haven, CT | Cardiovascular Disease | $57,354.85 |
| Raghavendra Charan Makam | Vero Beach, FL | Cardiovascular Disease | $56,690.00 |
| Rodney Samaan | Mission Hills, CA | Cardiovascular Disease | $53,906.65 |
| Norman Lepor | Beverly Hills, CA | $51,737.27 | |
| Americo Simonini | Los Angeles, CA | Cardiovascular Disease | $50,437.11 |
| Harvey Serota | Saint Louis, MO | Interventional Cardiology | $48,744.80 |
| Kenneth Burnham | Mobile, AL | Advanced Heart Failure and Transplant Cardiology | $48,565.20 |
| Hunter Champion | Columbus, GA | Cardiovascular Disease | $47,671.12 |
Prescribed Inpefa?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.